Identification | Back Directory | [Name]
Benzenecarboximidamide, 4-[[(5-phenyl-1H-imidazol-2-yl)methyl]amino]-2-(3-pyridinylmethoxy)- | [CAS]
2361160-57-6 | [Synonyms]
Kallikrein 5-IN-2 4-[[(5-Phenyl-2-imidazolyl)methyl]amino]-2-(3-pyridylmethoxy)benzimidamide Benzenecarboximidamide, 4-[[(5-phenyl-1H-imidazol-2-yl)methyl]amino]-2-(3-pyridinylmethoxy)- | [Molecular Formula]
C23H22N6O | [MOL File]
2361160-57-6.mol | [Molecular Weight]
398.46 |
Chemical Properties | Back Directory | [Boiling point ]
745.2±70.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.07±0.10(Predicted) | [color ]
Off-white to pink |
Hazard Information | Back Directory | [Uses]
Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching[1]. | [References]
[1] Walker AL, et al. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1454-1458. DOI:10.1016/j.bmcl.2019.04.022 |
|
|